OCRX Ocera Therapeutics, Inc.

0  -3%
Previous Close 1.37
Open 1.39
Price To book 2.05
Market Cap 31.39M
Shares 23,600,000
Volume 574,707
Short Ratio 0.43
Av. Daily Volume 3,208,290

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released January 30, 2017 - primary endpoint not met. Plans to meet with FDA 3Q 2017 - noted March 8, 2017.
OCR-002 (IV)
Hepatic encephalopathy
Phase 2a trial to be initiated 1H 2017.

Latest News

  1. ETFs with exposure to Ocera Therapeutics, Inc. : April 19, 2017
  2. Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem
  3. Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease (NAFLD)
  4. Ocera to Present at the 16th Annual Needham Healthcare Conference
  5. ETFs with exposure to Ocera Therapeutics, Inc. : March 27, 2017
  6. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  7. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  8. Here’s What’s Moving Immunomedics, Inc. (IMMU) And Ocera Therapeutics Inc (OCRX)
  9. Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  10. Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Ocera Therapeutics and Array Biopharma
  11. Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
  12. Five Penny Stocks to Buy Now
  13. Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference
  14. Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions, Inc., Natus Medical Incorporated, Northern Dynasty Minerals Ltd., Ocera Therapeutics, Inc., Psychemedics Corporation, RH and Stemline Therapeutics, Inc.
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc.
  16. Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
  17. ETFs with exposure to Ocera Therapeutics, Inc. : January 19, 2017
  18. Ocera Therapeutics (OCRX) Catches Eye: Stock Jumps 6.8%